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Available online 25 May 2016Stem cell therapies for neurological disorders are rapidlymoving towards use in clinical trials. Before initiation of
clinical trials, extensive pre-clinical validation in appropriate animal models is essential. However, grafts of
human cells into the rodent brain are rejected within weeks after transplantation and the standard methods of
immune-suppression for the purpose of studying human xenografts are not always sufﬁcient for the long-term
studies needed for transplanted human neurons to maturate, integrate and provide functional beneﬁts in the
host brain. Neonatal injections in rat pups using human fetal brain cells have been shown to desensitise the
host to accept human tissue grafts as adults, whilst not compromising their immune system. Here, we show
that differentiated human embryonic stem cells (hESCs) can be used for desensitisation to achieve long-term
graft survival of human stem cell-derived neurons in a xenograft setting, surpassing the time of conventional
pharmacological immune-suppressive treatments. The use of hESCs for desensitisation opens up for a wide-
spread use of the technique, which will be of great value when performing pre-clinical evaluation of stem cell-
derived neurons in animal models.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Human embryonic stem cells (hESCs) and induced pluripotent stem
cells (hiPSCs) have emerged as promising candidates to generate new
neurons for repair in neurological disorders such as Parkinson's disease
(Kirkeby et al., 2012; Kriks et al., 2011), Huntington's disease (Arber et
al., 2015; Delli Carri et al., 2013) and stroke (Kelly et al., 2004; Thored
et al., 2006). Clinical trials for diseases affecting the retina are already
under way (Cyranoski, 2013; Whiting et al., 2015) and the ﬁrst clinical
trials for Parkinson's disease are approaching in the near future
(Barker et al., 2015). In order to bring stem cell derived neurons to the
clinic in a safe and effective manner, the therapeutic potential of cells
must be extensively validated in preclinical rodent models of the corre-
sponding disease. Human neurons require several months, if not years
to achieve full maturation and integration after transplantation to the
human (Lindvall and Bjorklund, 2004; Piccini et al., 2000) and rodent
brain (Deacon et al., 1994; Pakzaban and Isacson, 1994). Therefore,
long-term transplantation studies that allow for the assessment oferimental Medical Science,
erg Neuroscience Center, Lund
.
. This is an open access article undersurvival, integration, and behavioral recovery are imperative. However,
human to rat xenografts using naïve immune-competent hosts trigger a
quick inﬂammation and immune response which destroys the trans-
plants within weeks (Brundin et al., 1988; Sloan et al., 1991; Widner
and Brundin, 1988). Currently, preclinical tests are therefore conducted
in either pharmacologically immune-suppressed (i.e. Cyclosporine A,
CsA) rats or in immune-compromised (i.e. athymic nude) rats
(Brundin et al., 1985; Grealish et al., 2014; Grealish et al., 2015; Kelly
et al., 2009). However, both these xenograft-models have shortcomings
when it comes to neural graft assessments: CsA requires daily i.p. injec-
tions and eventually leads to declining health of the animals which
limits CsA administration to a maximum of 18–20 weeks (Andoh and
Bennett, 1998; Murray et al., 1985). This precludes its use for long-
term testing, which is necessary to investigate maximal ﬁbre out-
growth, graft integration, and function. For long-term studies, athymic
nude rats that lack mature T-cells, can be used. However, despite
being excellent animal model for long-term xenograft experiments,
these animals are very prone to infections andhave to be kept in speciﬁc
pathogen-free conditions. Surgeries for creating lesions, cell transplan-
tation and vector injections as well as behavioral assessments require
repeated breaching of the barrier environment and thereby risking in-
fections and early termination of the experiment. Thus, neither of
these xenograft models is optimal for long-term multiplex assessment
of human grafts.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
79A. Heuer et al. / Experimental Neurology 282 (2016) 78–85In the early 1950′s it was shown that one way to circumvent the
problem of graft rejection of skin grafts in two different strains of mice
was to manipulate the host immune-system during its development
to recognise foreign cells as self (Billingham et al., 1953; Billingham
and Medawar, 1953). This concept has recently been translated to the
transplantation of neural tissue (Kelly et al., 2009), and desensitising
new-born rat pups at early postnatal ages with human cortical tissue
obtained from elective termination of pregnancies allows for engraft-
ment with similar cells during adulthood. This study convincingly
showed that the transplants could survive in desensitised rats to a sim-
ilar extent as cyclosporine treated rats without the need for additional
immune-suppression (Kelly et al., 2009; Zhang et al., 2013). Several lab-
oratories have tried to implement this approach in rats and mice withFig. 1. Rats desensitised with hESC-derived cells as neonates accept xenografts at a level compa
thebrain of CsA treated rats (CsAH9; n=7), (H–N) neonatal desensitised rats engrafted as adul
(Des hﬂ-iN; n = 2). Graft survival (A–B, H–I, O–P) and ﬁbre innervation (B, I) of transplants fro
immune responseswere assessedusing the followingmarkers respectively:microglia (Ox42: C,
I (Ox18: G, N, U). Graft sizeswere not different between the CsA control group and the neonatal
increased staining intensity in the rejection group (***= p b 0.001). Representative overview o
H, O = 500 μM; B, I, P = 100 μM; C–G, J–N, Q–U= 250 μM; and X = 2000 μM. Data represenmixed success (Janowski et al., 2012; Mattis et al., 2014; Roberton et
al., 2013; Zhang et al., 2013), and both the versatility and the mecha-
nismof the desensitisation remain elusive. There aremany possible rea-
sons for the failure to desensitise rats for xenograft acceptance, but the
most likely candidates are differences between host species and strains,
theMHCexpression of the donor cells used for inoculation aswell as the
state of the hosts immune systemduring inoculation, and the number of
cells injected (Billingham and Brent, 1956; Billingham et al., 1953;
Janowski et al., 2012; Kelly et al., 2009; Mattis et al., 2014; Roberton et
al., 2013).
Furthermore, thewidespread use of the neonatal desensitisation ap-
proach is currently dependent on the availability/access to primary fetal
tissue for injection. As this tissue is harvested fromelective terminationsrable to CsA treated hosts. (A–G) Characterisation of the survival and immune response in
tswith identical tissue (DesH9; n=8) and (O–U,W) desensitised rats engraftedwith hiNs
m each group were analysed using a speciﬁc marker for human NCAM. Inﬂammation and
J, Q), T-helper cells (CD4:D,K, R), T-cells (E, L, S),MHC-class II (Ox6: F,M, T) andMHC-class
desensitised rats (V). Optical density analysis for Ox42 positivemicroglia staining revealed
f the transplant and innervation of an H9-hESC graft in a desensitised host (X). Scalebars A,
t mean ± SEM. mean ± SEM.
Fig. 2. H9 hESC-derived cells desensitise the host to other hESC lines. Graft survival of (A) CsA immune-suppressed (CsA H9; n = 8 + 3), (B) identical (Des H9; n = 8 + 2, H9 to H9-
desensitised) and (C) different (Des RC17; n = 8 + 4, RC17 to H9-desensitised) hESC donor – host combinations. (E) A subset of animals was sacriﬁced after 6 weeks. The percentage
of survival was similar in all groups 18 weeks post-transplantation (E, n = 8 per group). Graft sizes were different between the three groups, with RC17 transplants being signiﬁcantly
larger, whilst the graft areas were similar for H9 grafts in CsA or desensitised hosts. Grafts of H9 hESC origin into naïve animals were readily rejected within 6 weeks post
transplantation (D; see also Fig. 3). Scalebar = 100 μM. All data in E are presented as mean ± SEM.
80 A. Heuer et al. / Experimental Neurology 282 (2016) 78–85of pregnancies, it is associated with very low availability, as well as eth-
ical andmajor logistical problems,making it a suboptimal cell source for
desensitisation studies. From an experimental perspective, off-the-shelf
cells that could be generated to the speciﬁc time of use would highly in-
crease the usefulness of the desensitisation method for preclinical as-
sessment of human stem cell based therapies. Here we show the
ability of hESC-derived cells to be used for desensitisation with compa-
rable efﬁciency to CsA and to protect against graft rejection for at least
up to 24 weeks post-transplantation. The use of hESC-derived neural
progenitors for desensitisation makes this method widely applicable
for any centre performing pre-clinical testing of human neurons.
2. Materials and methods
All research on laboratory animalswas conducted under local ethical
and personal licences and approved by the local ethical committee at
Lund University and the Swedish Department of Agriculture
(Jordbruksverket). Time-mated dams of the Sprague-Dawley strain
and adult females were purchased (Charles River, Germany) and kept
under standard laboratory conditions.
2.1. Induction of desensitisation
To ensure sufﬁcient exposure to the cells during the critical period
for desensitisation we injected all pups on post-natal day 2 and 4 i.p.
with 1 μl of pre-differentiated hESCs. The cells were differentiated ac-
cording to previously established protocols (Kirkeby et al., 2012) and
used for injections in a cell suspension of 100,000 cells/μl consisting ofFig. 3. Graft rejection response. Overview of characterisation of graft rejection of human to rat
engraftment. All rats were engrafted in parallel with the rats that were inoculated. Time-po
6 weeks (n = 2) and 18 weeks (n = 2) post transplantation. No graft was detected via staini
responses were strongest at the early time-point (2 weeks) and somewhat dampened at th
were visualized using antibodies against microglia (Ox42, D–E), T-helper cells (G–I), T-cells (
in H9-hESC grafts in fully immune-competent hosts demonstrates the capability of these
desensitisation approach.a mix of immature neural progenitors (day 16 of differentiation) and
postmitotic neurons (day 35 of differentiation).
2.2. Preparation of hESCs for desensitisation and transplantation
All human ESC lines H9 (WA09, WiCell) and RC17 (Roslin Cells,
hPSCreg #RCe021-A) were differentiated towards neural progenitors
as previously described (Kirkeby et al., 2012). Human iN were derived
via direct conversion of human fetal lung ﬁbroblast as described previ-
ously (Pﬁsterer et al., 2011). H9-Cre cells were generated by in vitro
lentiviral transduction with a Synapsin-Cre construct. For intra-striatal
transplantation, 300,000 (75,000 cells/μl) cells from day 16 of differen-
tiation were grafted as previously described (Kirkeby et al., 2012).
2.3. Transplantation
Once adult (minimum 15 weeks), all animals received lesions to the
ascending dopaminergic ﬁbre bundle as described previously (Torres et
al., 2011). 4–5 weeks after the lesion the rats were engrafted using dif-
ferentiated H9 and RC17, Cre-recombinase expressing H9-hESCs, or
human induced neurons (hiNs). The group sizes of the respective exper-
iments were as follows: In experiment 1 we engrafted 16 rats with H9-
hESC-derived cells (CsA, n=7;Desensitised, n=9) and 2 ratswith iNs.
In experiment 2 we engrafted 28 rats using H9-hESC-derived cells (re-
jection, n = 7; CsA, n = 8 + 3; Desensitised, n = 8 + 2) and 12 rats
using RC17 hESC (n = 8 + 4). For the assessment of breaching the
blood brain barrier we engrafted 4 rats using H9-hESC-derived cells
and 6 rats using Cre-recombinase expressing H9-hESC-derived cells.xenografts in fully immune-competent rat hosts over the time-course of 18 weeks post-
ints for assessment of the immune and inﬂammation responses were 2 weeks (n = 3),
ng for human NCAM (A–C) later than the 2 week time-point. Inﬂammation and immune
e last time-point of assessment (18 weeks). The respective inﬁltration of immune cells
J–L), MHC-class I (M–O), and MHC-class II (P–R). Scalebar = 200 μM. The rejection seen
cells to elicit an immune response as well as the need and validity of the neonatal
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nates: AP: +1.2, ML:−2.6, DV (from dura):−4.5 and AP: +0.5, ML:
−3.0, DV:−4.5, with the incisor bar set at−2.4. All cell suspensions
were done in one 2 μl deposit per injection tract. Cells were infused at
a speed of 1 μl per minute with 3min for diffusion after each placement
(Grealish et al., 2015).
Non-desensitised rats that were placed in the pharmacological im-
mune-suppression group received daily i.p. injections of Cyclosporine
(10 mg/kg) starting 1 day before transplantation.
2.4. Immunohistochemistry
All rats were perfused using ice-cold 4% PFA, brains were placed in
25% sucrose and cut coronal in a 1:12 series at a thickness of 35 μm. Im-
munohistochemistry was performed as stated in (Grealish et al., 2015).
Primary antibodies against hNCAM (Santa Cruz, AB106, monoclonal,
mouse, 1:1000); Ox42(CD11b) (Serotec, MCA275G, monoclonal,
mouse, 1:1000), GFAP (DAKO, Z0034, polyclonal, rabbit, 1:1000), CD4
(Abcam, AB33775, monoclonal, mouse, 1:1000), CD8 (Serotec,
MCA48G, monoclonal, mouse 1:1000), Ox6 (Abcam, AB23990, mono-
clonal, mouse, 1:500), Ox18 (Abcam, AB33752, monoclonal, mouse,
1:500), HuNu (Chemicon, MAB1281/87, monoclonal, mouse, 1:500),
GFP (Abcam, AB13970, polyclonal, chicken, 1:1000), Cre-recombinase
(BioLegend, PRB-106P, polyclonal, rabbit, 1:1000) were used.
2.5. Quantiﬁcation of graft area and microglia response
A series of coronal sections (35 μm; 1:12) was stained for hNCAM
and photographed using a Leica DMI600B microscope. The area of the
graft core was quantiﬁed using ImageJ software (Version 1.50d, Nation-
al Institues of Health, USA). Data are presented as the sum of all graft
areas corrected for series. To estimate the microglia response we took
images of three coronal sections stained for Ox42 in which the trans-
plant location was clearly visible from the animals of the CsA-im-
mune-suppressed, the neonatal desensitised and the rejection group
(weeks 2 and 6, n = 5). Optical staining intensity was measured using
ImageJ software (V1.50d, National Institues of Health, USA) calibrated
with an optical density table (NIH) and Rodbard function (Heuer et al.,
2012). We present the O.D. values of the Ox42 staining by subtraction
of the intact striatum from the engrafted striatum.
2.6. Statistics
All data were analysed using the software package for the social sci-
ence (SPSS) version 22.0 using a signiﬁcance level of α= 0.05. Data
were analysed using independent samples Student's t-test and one-
way analysis of variance with Bonferroni corrected α for multiple com-
parisons, where appropriate.
3. Results
3.1. Desensitisation with pre-differentiated hESCs and subsequent engraft-
ment of similar cells prevents graft rejection comparable to CsA
We injected new-born rat pups (n = 9) at early post-natal time-
points in view of desensitising them for subsequent neural xenograftsFig. 4. Characterisation of reopening the BloodBrain Barrier. Rats thatwere neonatally desensitis
H9-hESCs (DesH9AAV; n=4;A–F‴) or Cre-recombinase expressingH9-hESCs (DesH9-Cre AA
transplantation) to assesswhether thiswould trigger an immune response causing the rejection
F‴) or a CRE-activatable direction inverse orientation (DIO) AAV-vector with a cassette encodin
the cell population of interest. Transplants of both groups do survive long-term (N24weeks) in
responses (CD4: D, I; CD8: E, J). Immune responses do not cause a rejection of the transplant w
visualized using immune-ﬂuorescent antibodies against DAPI (F) human nuclei (HuNU: F′), and
tissue (E‴). Selective transgene expression in the donor cells is demonstrated using ﬂuorescent
merge (L) shows a cell that selectively expressed the EYFP reporter, clearly demonstrating the
insets 50 μM; F–F‴= 250 μM; G = 1000 μM, inset 50 μM; H–J = 1000 μM, inset 25 μM, K–K″as adults. To mimic the heterogeneous composition of human fetal tis-
sue, and to cover all cellular stages of graft maturation we used a mix
of hESC-derived neural progenitors and post-mitotic neurons for injec-
tion. After a minimum of 15weeks, the rats received unilateral 6-OHDA
lesions and were transplanted 4–5 weeks later with neural progenitors
prepared from the sameH9hESC line and using the same differentiation
protocol as for neonatal desensitisation. In parallel, a group of naïve lit-
termates (n = 7) rats were also lesioned and transplanted with the
same batch of cells. These rats were exposed to our normal regime of
daily injections of CsA (10 mg/kg) to prevent graft rejection.
When analysing the engrafted brains 18–22weeks after transplanta-
tion, we found that 8/9 animals in the desensitised group and 7/7 ani-
mals in the CsA treated groups had surviving grafts. Staining for
human speciﬁc neural cell adhesion molecule (hNCAM) conﬁrmed
that both groups contained neuron-rich grafts and revealed no differ-
ence in appearance or innervation of the grafted cells (Fig. 1, A–B; H–
I; X). Estimations of graft area (Fig. 1, V) based on the hNCAM staining
revealed that the grafts of CsA treated rats and neonatal desensitised
rats were of similar size (t13=−0.873, p=n.s.). The immune response
of the host after the xenograftingwas similar in both groups (Fig. 1, C–G
and J–N), differing only on the few CD8-positive T-cells that could be
found in the desensitised group (Fig. 1, E and L).
Optical density (O.D.) analysis for the Ox42/cd11bmicroglia staining
revealed an increased microglia response between the CsA immune-
suppressed, the neonatal desensitised and the rejection group
(F2,20, = 24.89, p b 0.001). There was a trend for slightly higher
micrcroglia activation in the desensitised rats compared to CsA treated
animals, but this difference failed to reach statistical signiﬁcance (p =
n.s.). The graft rejection group on the other hand had a signiﬁcant in-
crease in O.D. staining intensity compared to both groups (both,
p b 0.001) (Fig. 1W).
This demonstrates that neonatal desensitisation using differentiated
hESCs is a viable alternative to pharmacological immunosuppressive
compounds. To probe the versatility of the desensitisation, animals
that were desensitised using pre-differentiated H9-hESCs as new-
borns, were engrafted after reaching adulthood with human induced
neurons (iNs, n = 2) obtained from reprogrammed human fetal ﬁbro-
blasts (Pﬁsterer et al., 2011). These animals displayed a full immune re-
sponse against the foreign tissue (Fig. 1, P-U) and few, if any, surviving
human cells/ﬁbres could be detected 10weeks post engraftment (Fig. 1,
O–P).
3.2. Desensitisation using differentiated hESCs prevent graft rejection of
cells neural cells differentiated from other hESC lines
To test the robustness of hESC-based desensitisation, and to address
the speciﬁcity of the desensitisation approach further, we set up an ex-
periment where we compared CsA treated rats (n = 8 + 2, 18 weeks
and 6 weeks survival, respectively) to two groups of rats that were
desensitised using H9-derived cells and subsequently engrafted them
during adulthood with identically differentiated cells from either the
same hESC line (H9-hESCs, n = 8 + 2) or from a different hESC line
(RC17-hESCs, n = 8 + 4).
When analysing the grafts after 18–24 weeks, we found that neona-
tal desensitisation resulted in long-term graft survival in both
desensitised groups as well as in the CsA control group (CsA H9; n =ed using predifferentiatedH9-hESCs and subsequently engrafted in adulthoodusing either
V; n=6;G–L)were subjected to a third opening of the blood brain barrier (after lesion and
of the transplant (A).We either usedaGFP labelledAAV-vector to infect thehost tissue (B–
g for EYFP to selectively infect the Cre-recombinase expressing donor cells (G–L) to select
the rodent brain (B, G) and display limited inﬂammation (microglia; Ox42: C, H) and T-cell
ithin the four weeks after the respective AAV-transduction. Infection of the host cells was
GFP (F″). The composite merge shows the selective expression of the reporter in the host
antibodies against human NCAM (J), Cre-recombinase (K′) and eYFP (K″). The composite
expression of nuclear Cre-recombinase and expression of EYFP. Scalebars: B–E = 500 μM;
= 1000 μM, inset =20 μM; L = 100 μM.
84 A. Heuer et al. / Experimental Neurology 282 (2016) 78–858) to a similar extent (Fig. 2, A–C, E–F). When assessing graft sizes (Fig.
2, E) we found a signiﬁcant difference between the three transplant
groups (Group, F2,12 = 8.87, p b 0.01). Post-hoc assessment (Bonferroni
corrected α) revealed that the difference was due to the cell line used
(Des RC17 N Des H9 and Des RC17 N CsA H9, both: p b 0.05) whereas
the grafts from the H9-donor cells were of similar size, irrespective of
immunosuppression regime applied (Des= CsA, p= n.s.). When com-
paring the RC17 graft survival and appearance with other experiments
where we use CsA or nude rats for immunosuppression (Supplementa-
ry Fig. 1), we did not see a major difference to the experiments in this
study where we use H9 desensitised rats as hosts, and therefore we as-
cribe this difference in graft size to differences in the cell line, rather
than differences in the host response.
In contrast, naïve rats (n = 7) that were engrafted in parallel using
the same pre-differentiated H9-hESCs but received no form of im-
mune-suppression showed a rapid rejection of the transplants within
6 weeks post engraftment (Fig. 2, D; Fig. 3 A-R). The appropriate im-
mune reaction to the engrafted cells was accompanied by an early inﬁl-
tration of microglia as well as a large amount of CD8 positive T-cells
inﬁltrating the entire transplant. There was an abundance of MHC-
class I and II positive cells and graft rejection was completed within
6 weeks post transplantation. The immune response was somewhat
dampened after 18 weeks corresponding to the completed rejection of
the foreign tissue. This demonstrates that the hESC-derived cells as
such are immunogenic and are able to trigger an appropriate immune
response, thereby leading to a rapid rejection of the transplant.
3.3. Breaching the blood brain barrier after engraftment does not lead to
subsequent rejection of the transplant
In some experimental setups it is necessary to repeatedly reopen the
blood brain barrier (BBB) again after engraftment, for example when
using novel tracing methods (Grealish et al., 2015; Wickersham et al.,
2007) or to transduce the grafts when using optogenetic or
chemogenetic techniques (Aldrin-Kirk et al., 2016; Bryson et al., 2014;
Steinbeck et al., 2015; Weick et al., 2010). We tested if breaching the
BBB with a second injection, leading to the unavoidable introduction
of lymphocytes, would lead to spontaneous graft rejection in two differ-
ent experimental paradigms. For both experiments, we used hosts that
were desensitised with pre-differentiated H9-hESCs and subsequently
grafted with two different batches of differentiated H9 hESCs as adults.
One group (n = 4) received transplants of the unmodiﬁed hESCs,
whereas a second group (n = 6) received hESCs expressing Cre-
recombinase. After maturation for 20 weeks in vivo, these animals
were injected with AAV vectors that either targets the host brain
(hESC, n = 4) or the transplanted cells (hESC-Cre; n = 6) (Fig. 4, A).
When we analysed the animals 4 weeks post-vector surgery
(N24 weeks post- transplantation), we found similar levels of survival
in the AAV-GFP injected group (4/4) and in the CRE-activatable AAV-
DIO-EYFP injected group (4/6), with surviving healthy transplants in
both groups (Fig. 4 B and G). Selective transduction of the host (Fig. 4,
F–F‴) and the graft (Fig. 4, K–L) could be demonstrated via expression
of ﬂuorescent markers. The host immune response against the graft was
weak and comparable to the ﬁrst two experiments (Fig. 4 C–E; H–J comp
to Fig. 1, J–N), differing only in the somewhat heightening ofmicroglial ac-
tivation in the graft core of the hESC-Cre transplant (Fig. 4, H).
4. Discussion
In order to develop better long-term xenograft transplantations par-
adigms for evaluating grafts of humanneurons, we sought to investigate
the extent to which neonatal desensitisation using hESC-derived pro-
genitors and neurons could prevent xenograft rejection of hESC-derived
neural progenitors when engrafted into adult rats. For that purpose we
set up several experiments to directly compare the neonatal
desensitisation approach to conventional pharmacological immune-suppression using CsA, as well as to investigate to which extent one
cell line (H9) can be used for desensitisation towards a different cell
line (H9 vs RC17) or towards different types of cells (ES-derived neu-
rons vs iNs).
First we compared the graft survival and immune reaction of rats
that were transplanted with H9-hESC-derived neural progenitors into
either rats that were pharmacological immune-suppressed hosts using
CsA or into rats that were desensitised using identical cells at early neo-
natal ages. Whereas there is some discrepancy in the literature as to
whether the desensitisation approach works (Janowski et al., 2012;
Kelly et al., 2009), in the present setting grafts of desensitised rats sur-
vived equally well as their immune-suppressed counterparts. There
was no obvious difference in the quality of the immune and inﬂamma-
tion response as assessed by antibody staining for T-helper cells and T-
cells, as well as MHC class I and II antigens. The few CD8+ cells that
could be detected in the transplant location of inoculated rats were
only sparse and not enough to clear the transplant. Furthermore they
are at similar levels as in reports of successful desensitisation using
fetal cells from other groups (Kelly et al., 2009). We found a slight in-
crease in the microglia activation in the desensitised rats compared to
the CsA immune-suppressed animals, however this was much below
the response to rejected transplants. Whether the grafts of desensitised
animals are immune-activated or immunized over time (Shinoda et al.,
1995;Winkler et al., 2005), could not be addressed by the current study.
The long-term studies that have been conducted thus far have shown
graft survival up to 40 weeks post-transplantation (Kelly et al., 2009).
Important to note is that the transplanted cells are highly immunogenic
as evidenced by the rapid and strong inﬂammation and rejection re-
sponses occurring in naïve, immune-competent rat hosts.
We noted that the desensitisation was somewhat speciﬁc to the
cells used for inoculation and subsequent transplantation. Neural
progenitors derived from two different hESC lines (H9 and RC17)
were equally protected from graft rejection when transplanted into
adult hosts that had been desensitised as neonates using H9-derived
cells, whereas iN cells generated via direct neural conversion of
human fetal lung ﬁbroblast elicited a strong microglial inﬂammation
and immune response with near complete rejection of all donor cell
material.
Failures in the desensitisation that have been reported previously
(Janowski et al., 2012; Mattis et al., 2014; Roberton et al., 2013), could
be attributed to differences in donor cell type, strain of rats and mice,
sex, age at inoculation, when compared to the initial report (Kelly et
al., 2009). Similar to Kelly et al. (2009), we here used rats of the
Sprague-Dawley strain which were desensitised before P5. In contrast,
studies using mice (Janowski et al., 2012; Mattis et al., 2014; Roberton
et al., 2013), different cells for inoculation: mix of hfNPCs and hNP1
cells, (Mattis et al., 2014), human glial-restricted progenitors or
human umbilical cord blood-derived neural stem cells (Janowski et al.,
2012) could not replicate the desensitisation. As such there is too
much variability between the different studies to draw ﬁrm conclusion
of the source of variation in successful desensitisation. However, the
data in this study show that neonatal desensitisation can be successful
when using this approach in rats of the Sprague-Dawley strain and
using hESC-derived cells for inoculation, similar to what was reported
in Kelly et al. (2009) using human fetal cells for desensitisation and
grafting. One major adaptation to the protocol of Kelly et al. (2009)
was the repeated injection of cells for desensitisation at post-natal
days 2 and 4. The approach of using readily available hESC derived
cells for neonatal desensitisation allows for repeated injections during
the critical period and thereby maximizes the chances that the animals
will receive a sufﬁcient dose of cells. To expose the rats to epitopes
expressed at different stages of graft maturation, we used a mixed pop-
ulation of progenitor cells from day 16 andmature neurons from day 35
of differentiation for the desensitisation.Whether any of these different
differentiation stages individually could be used for successful
desensitisation has to be determined in future studies.
85A. Heuer et al. / Experimental Neurology 282 (2016) 78–85We further showed that the neonatal desensitisation allowed for a
second breaching of the BBBwithout rejection of the grafted cells open-
ing up new avenues for the use of this model for long-term studies of
human stem cell transplants using novel tracing methods (Grealish et
al., 2015) or the use of optogenetic and chemogenetic approaches
(Aldrin-Kirk et al., 2016; Steinbeck et al., 2015).
In summary, our data shows that long-term survival beyond the du-
ration of conventional CsA treatment is robustly achieved when using
pre-differentiated hESCs for desensitisation. Compared with human
fetal tissue previously used for desensitisation, hESCs are easily accessi-
ble and can be prepared on demand, which immensely increases the
utility of this system when performing pre-clinical assessment of stem
cell derived neurons in xenograft models.
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